Hubei Key Laboratory of Biological Targeted Therapy

Wuhan, China

Hubei Key Laboratory of Biological Targeted Therapy

Wuhan, China
SEARCH FILTERS
Time filter
Source Type

Yin T.,Union Hospital | Yin T.,Huazhong University of Science and Technology | Yin T.,Hubei Key Laboratory of Biological Targeted Therapy | Wei H.,Union Hospital | And 8 more authors.
Chemotherapy | Year: 2011

Background/Aims: The polycomb protein Bmi-1 plays oncogenic roles in various cancers. Here we aimed to investigate the contribution of Bmi-1 on the malignant behaviors of pancreatic cancer such as chemoresistance, invasion and tumorigenesis. Methods and Results: The MTT cell proliferation assay showed that shRNA mediated Bmi-1 knockdown and enhanced the chemosensitivity of pancreatic cancer cells to gemcitabine. The transwell invasion assay showed that Bmi-1 knockdown inhibited the invasion of pancreatic cancer cells in vitro. Notably, the reduced abilities of chemoresistance and invasion were associated with the transition from the mesenchymal phenotype to the epithelial phenotype of pancreatic cancer cells. Moreover, Bmi-1 knockdown led to the inhibition of the PI3K-Akt pathway and disrupted the sphere-forming abilities of pancreatic cancer cells. A nude mouse xenograft experiment demonstrated that pancreatic cancer cells depleted of Bmi-1 showed weak tumorigenicity in vivo. Conclusion: Our data suggest that Bmi-1 plays an important role in the progression of pancreatic cancer and represents a novel target for antitumor therapy of pancreatic cancer. Copyright © 2012 S. Karger AG, Basel.


Yin T.,Huazhong University of Science and Technology | Yin T.,Hubei Key Laboratory of Biological Targeted Therapy | Wei H.,Huazhong University of Science and Technology | Gou S.,Huazhong University of Science and Technology | And 4 more authors.
International Journal of Molecular Sciences | Year: 2011

Pancreatic cancer is one of the most lethal malignancies with poor prognosis. Previously, we found that a subpopulation of cancer stem cells (CSCs) in the Panc-1 pancreatic cancer cell line could propagate to form spheres. Here we characterized the malignant phenotypes of the pancreatic cancer stem CD44+/CD24+ cells, which were enriched under sphere forming conditions as analyzed by flow cytometry. These cells demonstrated increased resistance to gemcitabine and increased migration ability. Moreover, these cells exhibited epithelial to mesenchymal transition characterized by a decreased level of the epithelial marker E-cadherin and an increased level of the mesenchymal marker vimentin. Notably, abnormal expression of Bmi-1, ABCG2, Cyclin D1 and p16 were found in Panc-1 CSCs. Our results suggest that targeted inhibition of CSCs represents a novel therapeutic approach to overcome chemoresistance and metastasis of pancreatic cancer. © 2011 by the authors; licensee MDPI, Basel, Switzerland.

Loading Hubei Key Laboratory of Biological Targeted Therapy collaborators
Loading Hubei Key Laboratory of Biological Targeted Therapy collaborators